<?xml version='1.0' encoding='UTF-8'?>
<document id="qualitative"><sentence id="qualitative.s0" text="In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations "><entity charOffset="89-97" id="qualitative.s0.e0" text="quinidine" type="active-ingredient" /><entity charOffset="109-119" id="qualitative.s0.e1" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s0.e0" e2="qualitative.s0.e1" id="qualitative.s0.p0" /></sentence><sentence id="qualitative.s1" text="In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations "><entity charOffset="61-70" id="qualitative.s1.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="109-119" id="qualitative.s1.e1" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s1.e0" e2="qualitative.s1.e1" id="qualitative.s1.p0" /></sentence><sentence id="qualitative.s2" text="In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations "><entity charOffset="73-82" id="qualitative.s2.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="109-119" id="qualitative.s2.e1" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s2.e0" e2="qualitative.s2.e1" id="qualitative.s2.p0" /></sentence><sentence id="qualitative.s3" text="Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine"><entity charOffset="103-121" id="qualitative.s3.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="9-21" id="qualitative.s3.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="127-139" id="qualitative.s3.e2" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s3.e0" e2="qualitative.s3.e2" id="qualitative.s3.p0" /></sentence><sentence id="qualitative.s4" text=" Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine."><entity charOffset="91-109" id="qualitative.s4.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="115-127" id="qualitative.s4.e1" text="amitriptyline" type="active-ingredient" /><pair ddi="true" e1="qualitative.s4.e0" e2="qualitative.s4.e1" id="qualitative.s4.p0" /></sentence><sentence id="qualitative.s5" text="Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine."><entity charOffset="145-154" id="qualitative.s5.e0" text="imipramine" type="active-ingredient" /><entity charOffset="90-108" id="qualitative.s5.e1" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="true" e1="qualitative.s5.e0" e2="qualitative.s5.e1" id="qualitative.s5.p0" /></sentence><sentence id="qualitative.s6" text="Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine"><entity charOffset="90-108" id="qualitative.s6.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="129-140" id="qualitative.s6.e1" text="clomipramine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s6.e0" e2="qualitative.s6.e1" id="qualitative.s6.p0" /></sentence><sentence id="qualitative.s7" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="58-70" id="qualitative.s7.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="118-128" id="qualitative.s7.e1" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s7.e2" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s7.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s7.e0" e2="qualitative.s7.e3" id="qualitative.s7.p0" /></sentence><sentence id="qualitative.s8" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="58-70" id="qualitative.s8.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="208-227" id="qualitative.s8.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="qualitative.s8.e0" e2="qualitative.s8.e1" id="qualitative.s8.p0" /></sentence><sentence id="qualitative.s9" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance"><entity charOffset="64-71" id="qualitative.s9.e0" text="warfarin" type="active-ingredient" /><entity charOffset="198-217" id="qualitative.s9.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="qualitative.s9.e0" e2="qualitative.s9.e1" id="qualitative.s9.p0" /></sentence><sentence id="qualitative.s10" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance"><entity charOffset="90-102" id="qualitative.s10.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="170-180" id="qualitative.s10.e1" text="risperidone" type="active-ingredient" /><entity charOffset="207-217" id="qualitative.s10.e2" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s10.e0" e2="qualitative.s10.e2" id="qualitative.s10.p0" /></sentence><sentence id="qualitative.s11" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="118-128" id="qualitative.s11.e0" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s11.e1" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s11.e2" text="risperidone" type="active-ingredient" /><entity charOffset="73-81" id="qualitative.s11.e3" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s11.e2" e2="qualitative.s11.e3" id="qualitative.s11.p0" /></sentence><sentence id="qualitative.s12" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="208-227" id="qualitative.s12.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="73-81" id="qualitative.s12.e1" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s12.e0" e2="qualitative.s12.e1" id="qualitative.s12.p0" /></sentence><sentence id="qualitative.s13" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="208-227" id="qualitative.s13.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="73-81" id="qualitative.s13.e1" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s13.e0" e2="qualitative.s13.e1" id="qualitative.s13.p0" /></sentence><sentence id="qualitative.s14" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="118-128" id="qualitative.s14.e0" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s14.e1" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s14.e2" text="risperidone" type="active-ingredient" /><entity charOffset="73-81" id="qualitative.s14.e3" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s14.e2" e2="qualitative.s14.e3" id="qualitative.s14.p0" /></sentence><sentence id="qualitative.s15" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="208-227" id="qualitative.s15.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="58-70" id="qualitative.s15.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s15.e0" e2="qualitative.s15.e1" id="qualitative.s15.p0" /></sentence><sentence id="qualitative.s16" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance"><entity charOffset="170-180" id="qualitative.s16.e0" text="risperidone" type="active-ingredient" /><entity charOffset="207-217" id="qualitative.s16.e1" text="risperidone" type="active-ingredient" /><entity charOffset="64-71" id="qualitative.s16.e2" text="warfarin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s16.e1" e2="qualitative.s16.e2" id="qualitative.s16.p0" /></sentence><sentence id="qualitative.s17" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance"><entity charOffset="198-217" id="qualitative.s17.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="35-48" id="qualitative.s17.e1" text="sulfamethazine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s17.e0" e2="qualitative.s17.e1" id="qualitative.s17.p0" /></sentence><sentence id="qualitative.s18" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="98-110" id="qualitative.s18.e0" text="phenobarbital" type="active-ingredient" /><entity charOffset="118-128" id="qualitative.s18.e1" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s18.e2" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s18.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s18.e0" e2="qualitative.s18.e3" id="qualitative.s18.p0" /></sentence><sentence id="qualitative.s19" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="84-91" id="qualitative.s19.e0" text="rifampin" type="active-ingredient" /><entity charOffset="118-128" id="qualitative.s19.e1" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s19.e2" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s19.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s19.e0" e2="qualitative.s19.e3" id="qualitative.s19.p0" /></sentence><sentence id="qualitative.s20" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="208-227" id="qualitative.s20.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="98-110" id="qualitative.s20.e1" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="qualitative.s20.e0" e2="qualitative.s20.e1" id="qualitative.s20.p0" /></sentence><sentence id="qualitative.s21" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="118-128" id="qualitative.s21.e0" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s21.e1" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s21.e2" text="risperidone" type="active-ingredient" /><entity charOffset="84-91" id="qualitative.s21.e3" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s21.e2" e2="qualitative.s21.e3" id="qualitative.s21.p0" /></sentence><sentence id="qualitative.s22" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance"><entity charOffset="35-48" id="qualitative.s22.e0" text="sulfamethazine" type="active-ingredient" /><entity charOffset="170-180" id="qualitative.s22.e1" text="risperidone" type="active-ingredient" /><entity charOffset="207-217" id="qualitative.s22.e2" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s22.e0" e2="qualitative.s22.e2" id="qualitative.s22.p0" /></sentence><sentence id="qualitative.s23" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="208-227" id="qualitative.s23.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="84-91" id="qualitative.s23.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s23.e0" e2="qualitative.s23.e1" id="qualitative.s23.p0" /></sentence><sentence id="qualitative.s24" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance"><entity charOffset="90-102" id="qualitative.s24.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="198-217" id="qualitative.s24.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="qualitative.s24.e0" e2="qualitative.s24.e1" id="qualitative.s24.p0" /></sentence><sentence id="qualitative.s25" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="118-128" id="qualitative.s25.e0" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s25.e1" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="qualitative.s25.e2" text="risperidone" type="active-ingredient" /><entity charOffset="58-70" id="qualitative.s25.e3" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s25.e2" e2="qualitative.s25.e3" id="qualitative.s25.p0" /></sentence><sentence id="qualitative.s26" text="The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole"><entity charOffset="118-127" id="qualitative.s26.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="40-64" id="qualitative.s26.e1" text="14-hydroxy-clarithromycin" type="metabolite" /><pair ddi="true" e1="qualitative.s26.e0" e2="qualitative.s26.e1" id="qualitative.s26.p0" /></sentence><sentence id="qualitative.s27" text="The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole"><entity charOffset="118-127" id="qualitative.s27.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="21-34" id="qualitative.s27.e1" text="clarithromycin" type="active-ingredient" /><entity charOffset="51-64" id="qualitative.s27.e2" text="clarithromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s27.e0" e2="qualitative.s27.e2" id="qualitative.s27.p0" /></sentence><sentence id="qualitative.s28" text="Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole"><entity charOffset="0-13" id="qualitative.s28.e0" text="Clarithromycin" type="active-ingredient" /><entity charOffset="115-124" id="qualitative.s28.e1" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s28.e0" e2="qualitative.s28.e1" id="qualitative.s28.p0" /></sentence><sentence id="qualitative.s29" text="Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts)."><entity charOffset="113-122" id="qualitative.s29.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="240-251" id="qualitative.s29.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s29.e0" e2="qualitative.s29.e1" id="qualitative.s29.p0" /></sentence><sentence id="qualitative.s30" text="Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver."><entity charOffset="52-59" id="qualitative.s30.e0" text="warfarin" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s30.e1" text="Omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s30.e0" e2="qualitative.s30.e1" id="qualitative.s30.p0" /></sentence><sentence id="qualitative.s31" text="Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts)."><entity charOffset="113-122" id="qualitative.s31.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="254-263" id="qualitative.s31.e1" text="ampicillin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s31.e0" e2="qualitative.s31.e1" id="qualitative.s31.p0" /></sentence><sentence id="qualitative.s32" text="Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts)."><entity charOffset="113-122" id="qualitative.s32.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="277-280" id="qualitative.s32.e1" text="iron" type="active-ingredient" /><pair ddi="true" e1="qualitative.s32.e0" e2="qualitative.s32.e1" id="qualitative.s32.p0" /></sentence><sentence id="qualitative.s33" text="Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver."><entity charOffset="42-49" id="qualitative.s33.e0" text="diazepam" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s33.e1" text="Omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s33.e0" e2="qualitative.s33.e1" id="qualitative.s33.p0" /></sentence><sentence id="qualitative.s34" text=" For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole"><entity charOffset="40-49" id="qualitative.s34.e0" text="atazanavir" type="active-ingredient" /><entity charOffset="134-143" id="qualitative.s34.e1" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s34.e0" e2="qualitative.s34.e1" id="qualitative.s34.p0" /></sentence><sentence id="qualitative.s35" text="Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus"><entity charOffset="45-54" id="qualitative.s35.e0" text="tacrolimus" type="active-ingredient" /><entity charOffset="89-98" id="qualitative.s35.e1" text="tacrolimus" type="active-ingredient" /><entity charOffset="30-39" id="qualitative.s35.e2" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s35.e1" e2="qualitative.s35.e2" id="qualitative.s35.p0" /></sentence><sentence id="qualitative.s36" text="Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver."><entity charOffset="0-9" id="qualitative.s36.e0" text="Omeprazole" type="active-ingredient" /><entity charOffset="65-73" id="qualitative.s36.e1" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s36.e0" e2="qualitative.s36.e1" id="qualitative.s36.p0" /></sentence><sentence id="qualitative.s37" text="For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole"><entity charOffset="54-63" id="qualitative.s37.e0" text="nelfinavir" type="active-ingredient" /><entity charOffset="133-142" id="qualitative.s37.e1" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s37.e0" e2="qualitative.s37.e1" id="qualitative.s37.p0" /></sentence><sentence id="qualitative.s38" text="A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations"><entity charOffset="55-62" id="qualitative.s38.e0" text="rifampin" type="active-ingredient" /><entity charOffset="132-140" id="qualitative.s38.e1" text="oxycodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s38.e0" e2="qualitative.s38.e1" id="qualitative.s38.p0" /></sentence><sentence id="qualitative.s39" text="A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone"><entity charOffset="57-68" id="qualitative.s39.e0" text="voriconazole" type="active-ingredient" /><entity charOffset="144-152" id="qualitative.s39.e1" text="oxycodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s39.e0" e2="qualitative.s39.e1" id="qualitative.s39.p0" /></sentence><sentence id="qualitative.s40" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,"><entity charOffset="198-217" id="qualitative.s40.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="56-64" id="qualitative.s40.e1" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s40.e0" e2="qualitative.s40.e1" id="qualitative.s40.p0" /></sentence><sentence id="qualitative.s41" text="Chronic administration of clozapine with risperidone may decrease the clearance of risperidone"><entity charOffset="26-34" id="qualitative.s41.e0" text="clozapine" type="active-ingredient" /><entity charOffset="41-51" id="qualitative.s41.e1" text="risperidone" type="active-ingredient" /><entity charOffset="83-93" id="qualitative.s41.e2" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s41.e0" e2="qualitative.s41.e2" id="qualitative.s41.p0" /></sentence><sentence id="qualitative.s42" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,"><entity charOffset="67-74" id="qualitative.s42.e0" text="rifampin" type="active-ingredient" /><entity charOffset="101-111" id="qualitative.s42.e1" text="risperidone" type="active-ingredient" /><entity charOffset="182-192" id="qualitative.s42.e2" text="risperidone" type="active-ingredient" /><entity charOffset="207-217" id="qualitative.s42.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s42.e0" e2="qualitative.s42.e3" id="qualitative.s42.p0" /></sentence><sentence id="qualitative.s43" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,"><entity charOffset="81-93" id="qualitative.s43.e0" text="phenobarbital" type="active-ingredient" /><entity charOffset="101-111" id="qualitative.s43.e1" text="risperidone" type="active-ingredient" /><entity charOffset="182-192" id="qualitative.s43.e2" text="risperidone" type="active-ingredient" /><entity charOffset="207-217" id="qualitative.s43.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s43.e0" e2="qualitative.s43.e3" id="qualitative.s43.p0" /></sentence><sentence id="qualitative.s44" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,"><entity charOffset="81-93" id="qualitative.s44.e0" text="phenobarbital" type="active-ingredient" /><entity charOffset="198-217" id="qualitative.s44.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="qualitative.s44.e0" e2="qualitative.s44.e1" id="qualitative.s44.p0" /></sentence><sentence id="qualitative.s45" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,"><entity charOffset="67-74" id="qualitative.s45.e0" text="rifampin" type="active-ingredient" /><entity charOffset="198-217" id="qualitative.s45.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="qualitative.s45.e0" e2="qualitative.s45.e1" id="qualitative.s45.p0" /></sentence><sentence id="qualitative.s46" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected"><entity charOffset="0-12" id="qualitative.s46.e0" text="Carbamazepine" type="active-ingredient" /><entity charOffset="160-172" id="qualitative.s46.e1" text="Carbamazepine" type="active-ingredient" /><entity charOffset="84-94" id="qualitative.s46.e2" text="risperidone" type="active-ingredient" /><entity charOffset="109-119" id="qualitative.s46.e3" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="qualitative.s46.e1" e2="qualitative.s46.e3" id="qualitative.s46.p0" /></sentence><sentence id="qualitative.s47" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected"><entity charOffset="0-12" id="qualitative.s47.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="160-172" id="qualitative.s47.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="100-119" id="qualitative.s47.e2" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="false" e1="qualitative.s47.e1" e2="qualitative.s47.e2" id="qualitative.s47.p0" /></sentence><sentence id="qualitative.s48" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,"><entity charOffset="101-111" id="qualitative.s48.e0" text="risperidone" type="active-ingredient" /><entity charOffset="182-192" id="qualitative.s48.e1" text="risperidone" type="active-ingredient" /><entity charOffset="207-217" id="qualitative.s48.e2" text="risperidone" type="active-ingredient" /><entity charOffset="56-64" id="qualitative.s48.e3" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s48.e2" e2="qualitative.s48.e3" id="qualitative.s48.p0" /></sentence><sentence id="qualitative.s49" text="Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels"><entity charOffset="65-75" id="qualitative.s49.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="119-129" id="qualitative.s49.e1" text="nisoldipine" type="active-ingredient" /><entity charOffset="20-28" id="qualitative.s49.e2" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s49.e1" e2="qualitative.s49.e2" id="qualitative.s49.p0" /></sentence><sentence id="qualitative.s50" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant"><entity charOffset="37-47" id="qualitative.s50.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="68-75" id="qualitative.s50.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s50.e0" e2="qualitative.s50.e1" id="qualitative.s50.p0" /></sentence><sentence id="qualitative.s51" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant"><entity charOffset="37-47" id="qualitative.s51.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="78-88" id="qualitative.s51.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s51.e0" e2="qualitative.s51.e1" id="qualitative.s51.p0" /></sentence><sentence id="qualitative.s52" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant"><entity charOffset="37-47" id="qualitative.s52.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="78-88" id="qualitative.s52.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s52.e0" e2="qualitative.s52.e1" id="qualitative.s52.p0" /></sentence><sentence id="qualitative.s53" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant"><entity charOffset="37-47" id="qualitative.s53.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="68-75" id="qualitative.s53.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s53.e0" e2="qualitative.s53.e1" id="qualitative.s53.p0" /></sentence><sentence id="qualitative.s54" text="Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect"><entity charOffset="118-134" id="qualitative.s54.e0" text="active metabolite" type="metabolite" /><entity charOffset="20-32" id="qualitative.s54.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s54.e0" e2="qualitative.s54.e1" id="qualitative.s54.p0" /></sentence><sentence id="qualitative.s55" text="Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect"><entity charOffset="20-32" id="qualitative.s55.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="39-48" id="qualitative.s55.e1" text="nefazodone" type="active-ingredient" /><entity charOffset="99-108" id="qualitative.s55.e2" text="nefazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s55.e0" e2="qualitative.s55.e2" id="qualitative.s55.p0" /></sentence><sentence id="qualitative.s56" text="Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days)"><entity charOffset="71-80" id="qualitative.s56.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s56.e1" text="Zonisamide" type="active-ingredient" /><pair ddi="false" e1="qualitative.s56.e0" e2="qualitative.s56.e1" id="qualitative.s56.p0" /></sentence><sentence id="qualitative.s57" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials."><entity charOffset="0-9" id="qualitative.s57.e0" text="Zonisamide" type="active-ingredient" /><entity charOffset="111-119" id="qualitative.s57.e1" text="valproate" type="active-ingredient" /><pair ddi="false" e1="qualitative.s57.e0" e2="qualitative.s57.e1" id="qualitative.s57.p0" /></sentence><sentence id="qualitative.s58" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials."><entity charOffset="82-90" id="qualitative.s58.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s58.e1" text="Zonisamide" type="active-ingredient" /><pair ddi="false" e1="qualitative.s58.e0" e2="qualitative.s58.e1" id="qualitative.s58.p0" /></sentence><sentence id="qualitative.s59" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials."><entity charOffset="0-9" id="qualitative.s59.e0" text="Zonisamide" type="active-ingredient" /><entity charOffset="93-105" id="qualitative.s59.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s59.e0" e2="qualitative.s59.e1" id="qualitative.s59.p0" /></sentence><sentence id="qualitative.s60" text="Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem"><entity charOffset="0-8" id="qualitative.s60.e0" text="Diltiazem" type="active-ingredient" /><entity charOffset="130-138" id="qualitative.s60.e1" text="Diltiazem" type="active-ingredient" /><entity charOffset="74-82" id="qualitative.s60.e2" text="quinidine" type="active-ingredient" /><entity charOffset="89-97" id="qualitative.s60.e3" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s60.e1" e2="qualitative.s60.e3" id="qualitative.s60.p0" /></sentence><sentence id="qualitative.s61" text="Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem"><entity charOffset="0-8" id="qualitative.s61.e0" text="diltiazem" type="active-ingredient" /><entity charOffset="130-138" id="qualitative.s61.e1" text="diltiazem" type="active-ingredient" /><entity charOffset="74-82" id="qualitative.s61.e2" text="quinidine" type="active-ingredient" /><entity charOffset="89-97" id="qualitative.s61.e3" text="quinidine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s61.e1" e2="qualitative.s61.e3" id="qualitative.s61.p0" /></sentence><sentence id="qualitative.s62" text="Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered"><entity charOffset="93-104" id="qualitative.s62.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="66-74" id="qualitative.s62.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s62.e0" e2="qualitative.s62.e1" id="qualitative.s62.p0" /></sentence><sentence id="qualitative.s63" text="Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine."><entity charOffset="50-59" id="qualitative.s63.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="102-111" id="qualitative.s63.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="21-43" id="qualitative.s63.e2" text="fosamprenavir/ritonavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s63.e1" e2="qualitative.s63.e2" id="qualitative.s63.p0" /></sentence><sentence id="qualitative.s64" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin"><entity charOffset="41-54" id="qualitative.s64.e0" text="sulfinpyrazone" type="active-ingredient" /><entity charOffset="96-109" id="qualitative.s64.e1" text="nitrofurantoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s64.e0" e2="qualitative.s64.e1" id="qualitative.s64.p0" /></sentence><sentence id="qualitative.s65" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial"><entity charOffset="96-109" id="qualitative.s65.e0" text="nitrofurantoin" type="active-ingredient" /><entity charOffset="138-151" id="qualitative.s65.e1" text="nitrofurantoin" type="active-ingredient" /><entity charOffset="26-35" id="qualitative.s65.e2" text="probenecid" type="active-ingredient" /><pair ddi="true" e1="qualitative.s65.e1" e2="qualitative.s65.e2" id="qualitative.s65.p0" /></sentence><sentence id="qualitative.s66" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin"><entity charOffset="96-109" id="qualitative.s66.e0" text="nitrofurantoin" type="active-ingredient" /><entity charOffset="26-35" id="qualitative.s66.e1" text="probenecid" type="active-ingredient" /><pair ddi="true" e1="qualitative.s66.e0" e2="qualitative.s66.e1" id="qualitative.s66.p0" /></sentence><sentence id="qualitative.s67" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial"><entity charOffset="41-54" id="qualitative.s67.e0" text="sulfinpyrazone" type="active-ingredient" /><entity charOffset="96-109" id="qualitative.s67.e1" text="nitrofurantoin" type="active-ingredient" /><entity charOffset="138-151" id="qualitative.s67.e2" text="nitrofurantoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s67.e0" e2="qualitative.s67.e2" id="qualitative.s67.p0" /></sentence><sentence id="qualitative.s68" text="Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption"><entity charOffset="20-40" id="qualitative.s68.e0" text="magnesium trisilicate" type="active-ingredient" /><entity charOffset="80-93" id="qualitative.s68.e1" text="nitrofurantoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s68.e0" e2="qualitative.s68.e1" id="qualitative.s68.p0" /></sentence><sentence id="qualitative.s69" text="The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers"><entity charOffset="20-28" id="qualitative.s69.e0" text="glyburide" type="active-ingredient" /><entity charOffset="110-120" id="qualitative.s69.e1" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s69.e0" e2="qualitative.s69.e1" id="qualitative.s69.p0" /></sentence><sentence id="qualitative.s70" text="The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers"><entity charOffset="112-122" id="qualitative.s70.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="20-28" id="qualitative.s70.e1" text="glipizide" type="active-ingredient" /><pair ddi="true" e1="qualitative.s70.e0" e2="qualitative.s70.e1" id="qualitative.s70.p0" /></sentence><sentence id="qualitative.s71" text="Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours."><entity charOffset="76-83" id="qualitative.s71.e0" text="rifampin" type="active-ingredient" /><entity charOffset="47-57" id="qualitative.s71.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="185-195" id="qualitative.s71.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="258-268" id="qualitative.s71.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="307-317" id="qualitative.s71.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="385-395" id="qualitative.s71.e5" text="fluconazole" type="active-ingredient" /><entity charOffset="438-448" id="qualitative.s71.e6" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s71.e0" e2="qualitative.s71.e6" id="qualitative.s71.p0" /></sentence><sentence id="qualitative.s72" text="After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). "><entity charOffset="76-86" id="qualitative.s72.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="137-147" id="qualitative.s72.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="28-37" id="qualitative.s72.e2" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s72.e1" e2="qualitative.s72.e2" id="qualitative.s72.p0" /></sentence><sentence id="qualitative.s73" text="There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole."><entity charOffset="116-126" id="qualitative.s73.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="60-73" id="qualitative.s73.e1" text="levonorgestrel" type="active-ingredient" /><pair ddi="false" e1="qualitative.s73.e0" e2="qualitative.s73.e1" id="qualitative.s73.p0" /></sentence><sentence id="qualitative.s74" text="There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole."><entity charOffset="39-55" id="qualitative.s74.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="116-126" id="qualitative.s74.e1" text="fluconazole" type="active-ingredient" /><pair ddi="false" e1="qualitative.s74.e0" e2="qualitative.s74.e1" id="qualitative.s74.p0" /></sentence><sentence id="qualitative.s75" text="The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment"><entity charOffset="29-41" id="qualitative.s75.e0" text="norethindrone" type="active-ingredient" /><entity charOffset="103-113" id="qualitative.s75.e1" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s75.e0" e2="qualitative.s75.e1" id="qualitative.s75.p0" /></sentence><sentence id="qualitative.s76" text="In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing."><entity charOffset="141-151" id="qualitative.s76.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="208-224" id="qualitative.s76.e1" text="ethinyl estradiol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s76.e0" e2="qualitative.s76.e1" id="qualitative.s76.p0" /></sentence><sentence id="qualitative.s77" text="Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing"><entity charOffset="54-70" id="qualitative.s77.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="0-10" id="qualitative.s77.e1" text="Fluconazole" type="active-ingredient" /><pair ddi="false" e1="qualitative.s77.e0" e2="qualitative.s77.e1" id="qualitative.s77.p0" /></sentence><sentence id="qualitative.s78" text="In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing."><entity charOffset="141-151" id="qualitative.s78.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="230-242" id="qualitative.s78.e1" text="norethindrone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s78.e0" e2="qualitative.s78.e1" id="qualitative.s78.p0" /></sentence><sentence id="qualitative.s79" text="Desipramine Blood levels of desipramine have increased with concurrent methadone administration."><entity charOffset="0-10" id="qualitative.s79.e0" text="desipramine" type="active-ingredient" /><entity charOffset="28-38" id="qualitative.s79.e1" text="desipramine" type="active-ingredient" /><entity charOffset="71-79" id="qualitative.s79.e2" text="methadone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s79.e1" e2="qualitative.s79.e2" id="qualitative.s79.p0" /></sentence><sentence id="qualitative.s80" text="In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptom"><entity charOffset="31-39" id="qualitative.s80.e0" text="methadone" type="active-ingredient" /><entity charOffset="121-129" id="qualitative.s80.e1" text="methadone" type="active-ingredient" /><entity charOffset="72-79" id="qualitative.s80.e2" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s80.e1" e2="qualitative.s80.e2" id="qualitative.s80.p0" /></sentence><sentence id="qualitative.s81" text="Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects"><entity charOffset="113-122" id="qualitative.s81.e0" text="zidovudine" type="active-ingredient" /><entity charOffset="40-48" id="qualitative.s81.e1" text="methadone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s81.e0" e2="qualitative.s81.e1" id="qualitative.s81.p0" /></sentence><sentence id="qualitative.s82" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered"><entity charOffset="40-48" id="qualitative.s82.e0" text="methadone" type="active-ingredient" /><entity charOffset="163-171" id="qualitative.s82.e1" text="methadone" type="active-ingredient" /><entity charOffset="103-111" id="qualitative.s82.e2" text="stavudine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s82.e1" e2="qualitative.s82.e2" id="qualitative.s82.p0" /></sentence><sentence id="qualitative.s83" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered"><entity charOffset="40-48" id="qualitative.s83.e0" text="methadone" type="active-ingredient" /><entity charOffset="163-171" id="qualitative.s83.e1" text="methadone" type="active-ingredient" /><entity charOffset="88-97" id="qualitative.s83.e2" text="didanosine" type="active-ingredient" /><entity charOffset="151-160" id="qualitative.s83.e3" text="didanosine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s83.e1" e2="qualitative.s83.e3" id="qualitative.s83.p0" /></sentence><sentence id="qualitative.s84" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine"><entity charOffset="40-48" id="qualitative.s84.e0" text="methadone" type="active-ingredient" /><entity charOffset="103-111" id="qualitative.s84.e1" text="stavudine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s84.e0" e2="qualitative.s84.e1" id="qualitative.s84.p0" /></sentence><sentence id="qualitative.s85" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine"><entity charOffset="88-97" id="qualitative.s85.e0" text="didanosine" type="active-ingredient" /><entity charOffset="151-160" id="qualitative.s85.e1" text="didanosine" type="active-ingredient" /><entity charOffset="40-48" id="qualitative.s85.e2" text="methadone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s85.e1" e2="qualitative.s85.e2" id="qualitative.s85.p0" /></sentence><sentence id="qualitative.s86" text="Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics"><entity charOffset="101-110" id="qualitative.s86.e0" text="zidovudine" type="active-ingredient" /><entity charOffset="27-35" id="qualitative.s86.e1" text="methadone" type="active-ingredient" /><pair ddi="false" e1="qualitative.s86.e0" e2="qualitative.s86.e1" id="qualitative.s86.p0" /></sentence><sentence id="qualitative.s87" text="Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented"><entity charOffset="0-8" id="qualitative.s87.e0" text="Phenytoin" type="active-ingredient" /><entity charOffset="80-89" id="qualitative.s87.e1" text="zidovudine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s87.e0" e2="qualitative.s87.e1" id="qualitative.s87.p0" /></sentence><sentence id="qualitative.s88" text="At low doses the differences are greater, with slow metabolizers attaining concentrations about 3 to 4 times higher than extensive metabolizers. In extensive metabolizers, saturation of the hydroxylation pathway (CYP2D6) results in greater-than-linear increases in plasma levels following administration of RYTHMOL SR capsules. In slow metabolizers, propafenone pharmacokinetics is linear. Because the difference decreases at high doses and is mitigated by the lack of the active 5-hydroxymetabolite in the slow metabolizers, and because steady-state conditions are achieved after 4 to 5 days of dosing in all patients, the recommended dosing regimen of RYTHMOL SR is the same for all patients. The larger inter-subject variability in blood levels require that the dose of the drug be titrated carefully in patients with close attention paid to clinical and ECG evidence of toxicity"><entity charOffset="350-360" id="qualitative.s88.e0" text="propafenone" type="active-ingredient" /><entity charOffset="307-325" id="qualitative.s88.e1" text="RYTHMOL SR capsules" type="drug-product" /><pair ddi="true" e1="qualitative.s88.e0" e2="qualitative.s88.e1" id="qualitative.s88.p0" /></sentence><sentence id="qualitative.s89" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="35-45" id="qualitative.s89.e0" text="desipramine" type="active-ingredient" /><entity charOffset="228-238" id="qualitative.s89.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s89.e0" e2="qualitative.s89.e1" id="qualitative.s89.p0" /></sentence><sentence id="qualitative.s90" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="228-238" id="qualitative.s90.e0" text="propafenone" type="active-ingredient" /><entity charOffset="60-68" id="qualitative.s90.e1" text="ritonavir" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s90.e2" text="ritonavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s90.e0" e2="qualitative.s90.e2" id="qualitative.s90.p0" /></sentence><sentence id="qualitative.s91" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="228-238" id="qualitative.s91.e0" text="propafenone" type="active-ingredient" /><entity charOffset="71-80" id="qualitative.s91.e1" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="qualitative.s91.e0" e2="qualitative.s91.e1" id="qualitative.s91.p0" /></sentence><sentence id="qualitative.s92" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="140-151" id="qualitative.s92.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="228-238" id="qualitative.s92.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s92.e0" e2="qualitative.s92.e1" id="qualitative.s92.p0" /></sentence><sentence id="qualitative.s93" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="228-238" id="qualitative.s93.e0" text="propafenone" type="active-ingredient" /><entity charOffset="48-57" id="qualitative.s93.e1" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s93.e0" e2="qualitative.s93.e1" id="qualitative.s93.p0" /></sentence><sentence id="qualitative.s94" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="128-137" id="qualitative.s94.e0" text="saquinavir" type="active-ingredient" /><entity charOffset="228-238" id="qualitative.s94.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s94.e0" e2="qualitative.s94.e1" id="qualitative.s94.p0" /></sentence><sentence id="qualitative.s95" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="60-68" id="qualitative.s95.e0" text="ritonavir" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s95.e1" text="ritonavir" type="active-ingredient" /><entity charOffset="228-238" id="qualitative.s95.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s95.e1" e2="qualitative.s95.e2" id="qualitative.s95.p0" /></sentence><sentence id="qualitative.s96" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone"><entity charOffset="103-114" id="qualitative.s96.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="228-238" id="qualitative.s96.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s96.e0" e2="qualitative.s96.e1" id="qualitative.s96.p0" /></sentence><sentence id="qualitative.s97" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. "><entity charOffset="454-464" id="qualitative.s97.e0" text="metabolites" type="metabolite" /><entity charOffset="30-37" id="qualitative.s97.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s97.e0" e2="qualitative.s97.e1" id="qualitative.s97.p0" /></sentence><sentence id="qualitative.s98" text="Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4. "><entity charOffset="132-142" id="qualitative.s98.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="48-59" id="qualitative.s98.e1" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s98.e0" e2="qualitative.s98.e1" id="qualitative.s98.p0" /></sentence><sentence id="qualitative.s99" text="In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma."><entity charOffset="57-67" id="qualitative.s99.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="44-50" id="qualitative.s99.e1" text="digoxin" type="active-ingredient" /><entity charOffset="103-109" id="qualitative.s99.e2" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s99.e0" e2="qualitative.s99.e2" id="qualitative.s99.p0" /></sentence><sentence id="qualitative.s100" text="It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)"><entity charOffset="181-190" id="qualitative.s100.e0" text="ampicillin" type="active-ingredient" /><entity charOffset="34-45" id="qualitative.s100.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s100.e0" e2="qualitative.s100.e1" id="qualitative.s100.p0" /></sentence><sentence id="qualitative.s101" text="It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)."><entity charOffset="34-45" id="qualitative.s101.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="212-218" id="qualitative.s101.e1" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s101.e0" e2="qualitative.s101.e1" id="qualitative.s101.p0" /></sentence><sentence id="qualitative.s102" text="It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)"><entity charOffset="34-45" id="qualitative.s102.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="167-178" id="qualitative.s102.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s102.e0" e2="qualitative.s102.e1" id="qualitative.s102.p0" /></sentence><sentence id="qualitative.s103" text="lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, "><entity charOffset="120-129" id="qualitative.s103.e0" text="atazanavir" type="active-ingredient" /><entity charOffset="0-36" id="qualitative.s103.e1" text="lansoprazole delayed-release capsules" type="drug-product" /><pair ddi="true" e1="qualitative.s103.e0" e2="qualitative.s103.e1" id="qualitative.s103.p0" /></sentence><sentence id="qualitative.s104" text="It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)"><entity charOffset="200-203" id="qualitative.s104.e0" text="iron" type="active-ingredient" /><entity charOffset="34-45" id="qualitative.s104.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s104.e0" e2="qualitative.s104.e1" id="qualitative.s104.p0" /></sentence><sentence id="qualitative.s105" text="It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)"><entity charOffset="34-70" id="qualitative.s105.e0" text="lansoprazole delayed-release capsules" type="drug-product" /><entity charOffset="240-243" id="qualitative.s105.e1" text="iron" type="active-ingredient" /><pair ddi="true" e1="qualitative.s105.e0" e2="qualitative.s105.e1" id="qualitative.s105.p0" /></sentence><sentence id="qualitative.s106" text="It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)"><entity charOffset="34-70" id="qualitative.s106.e0" text="lansoprazole delayed-release capsules" type="drug-product" /><entity charOffset="252-263" id="qualitative.s106.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s106.e0" e2="qualitative.s106.e1" id="qualitative.s106.p0" /></sentence><sentence id="qualitative.s107" text="It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)"><entity charOffset="212-221" id="qualitative.s107.e0" text="ampicillin" type="active-ingredient" /><entity charOffset="34-70" id="qualitative.s107.e1" text="lansoprazole delayed-release capsules" type="drug-product" /><pair ddi="true" e1="qualitative.s107.e0" e2="qualitative.s107.e1" id="qualitative.s107.p0" /></sentence><sentence id="qualitative.s108" text="Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus"><entity charOffset="30-41" id="qualitative.s108.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="47-56" id="qualitative.s108.e1" text="tacrolimus" type="active-ingredient" /><entity charOffset="93-102" id="qualitative.s108.e2" text="tacrolimus" type="active-ingredient" /><pair ddi="true" e1="qualitative.s108.e0" e2="qualitative.s108.e2" id="qualitative.s108.p0" /></sentence><sentence id="qualitative.s109" text="Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir,"><entity charOffset="0-36" id="qualitative.s109.e0" text="Lansoprazole delayed-release capsules" type="drug-product" /><entity charOffset="148-157" id="qualitative.s109.e1" text="atazanavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s109.e0" e2="qualitative.s109.e1" id="qualitative.s109.p0" /></sentence><sentence id="qualitative.s110" text="It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)"><entity charOffset="231-237" id="qualitative.s110.e0" text="digoxin" type="active-ingredient" /><entity charOffset="34-70" id="qualitative.s110.e1" text="lansoprazole delayed-release capsules" type="drug-product" /><pair ddi="true" e1="qualitative.s110.e0" e2="qualitative.s110.e1" id="qualitative.s110.p0" /></sentence><sentence id="qualitative.s111" text="Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels"><entity charOffset="101-109" id="qualitative.s111.e0" text="verapamil" type="active-ingredient" /><entity charOffset="40-46" id="qualitative.s111.e1" text="lithium" type="active-ingredient" /><entity charOffset="111-117" id="qualitative.s111.e2" text="lithium" type="active-ingredient" /><entity charOffset="173-179" id="qualitative.s111.e3" text="lithium" type="active-ingredient" /><pair ddi="true" e1="qualitative.s111.e0" e2="qualitative.s111.e3" id="qualitative.s111.p0" /></sentence><sentence id="qualitative.s112" text="A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil"><entity charOffset="14-23" id="qualitative.s112.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="121-129" id="qualitative.s112.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s112.e0" e2="qualitative.s112.e1" id="qualitative.s112.p0" /></sentence><sentence id="qualitative.s113" text="7.19 Phenobarbital Phenobarbital therapy may increase verapamil clearance. 7.20 Rifampin Therapy with rifampin may markedly reduce oral verapamil bioavailability. 7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. "><entity charOffset="5-17" id="qualitative.s113.e0" text="Phenobarbital" type="active-ingredient" /><entity charOffset="19-31" id="qualitative.s113.e1" text="Phenobarbital" type="active-ingredient" /><entity charOffset="54-62" id="qualitative.s113.e2" text="verapamil" type="active-ingredient" /><entity charOffset="136-144" id="qualitative.s113.e3" text="verapamil" type="active-ingredient" /><entity charOffset="181-189" id="qualitative.s113.e4" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s113.e1" e2="qualitative.s113.e4" id="qualitative.s113.p0" /></sentence><sentence id="qualitative.s114" text="ncreased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels"><entity charOffset="39-45" id="qualitative.s114.e0" text="lithium" type="active-ingredient" /><entity charOffset="110-116" id="qualitative.s114.e1" text="lithium" type="active-ingredient" /><entity charOffset="172-178" id="qualitative.s114.e2" text="lithium" type="active-ingredient" /><entity charOffset="100-108" id="qualitative.s114.e3" text="verapamil" type="active-ingredient" /><pair ddi="false" e1="qualitative.s114.e2" e2="qualitative.s114.e3" id="qualitative.s114.p0" /></sentence><sentence id="qualitative.s115" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. "><entity charOffset="91-100" id="qualitative.s115.e0" text="prednisone" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s115.e1" text="verapamil" type="active-ingredient" /><entity charOffset="213-221" id="qualitative.s115.e2" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s115.e0" e2="qualitative.s115.e2" id="qualitative.s115.p0" /></sentence><sentence id="qualitative.s116" text="Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol"><entity charOffset="0-8" id="qualitative.s116.e0" text="Verapamil" type="active-ingredient" /><entity charOffset="50-56" id="qualitative.s116.e1" text="ethanol" type="active-ingredient" /><entity charOffset="98-104" id="qualitative.s116.e2" text="ethanol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s116.e0" e2="qualitative.s116.e2" id="qualitative.s116.p0" /></sentence><sentence id="qualitative.s117" text="Concomitant administration of R-verapamil can decrease the clearance of paclitaxel."><entity charOffset="32-40" id="qualitative.s117.e0" text="verapamil" type="active-ingredient" /><entity charOffset="72-81" id="qualitative.s117.e1" text="paclitaxel" type="active-ingredient" /><pair ddi="true" e1="qualitative.s117.e0" e2="qualitative.s117.e1" id="qualitative.s117.p0" /></sentence><sentence id="qualitative.s118" text="Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil"><entity charOffset="151-159" id="qualitative.s118.e0" text="verapamil" type="active-ingredient" /><entity charOffset="102-110" id="qualitative.s118.e1" text="ritonavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s118.e0" e2="qualitative.s118.e1" id="qualitative.s118.p0" /></sentence><sentence id="qualitative.s119" text="However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium"><entity charOffset="78-84" id="qualitative.s119.e0" text="lithium" type="active-ingredient" /><entity charOffset="135-141" id="qualitative.s119.e1" text="lithium" type="active-ingredient" /><entity charOffset="25-33" id="qualitative.s119.e2" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s119.e1" e2="qualitative.s119.e2" id="qualitative.s119.p0" /></sentence><sentence id="qualitative.s120" text="Inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of verapamil."><entity charOffset="26-33" id="qualitative.s120.e0" text="rifampin" type="active-ingredient" /><entity charOffset="79-87" id="qualitative.s120.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s120.e0" e2="qualitative.s120.e1" id="qualitative.s120.p0" /></sentence><sentence id="qualitative.s121" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. "><entity charOffset="50-65" id="qualitative.s121.e0" text="cyclophosphamide" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s121.e1" text="verapamil" type="active-ingredient" /><entity charOffset="213-221" id="qualitative.s121.e2" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s121.e0" e2="qualitative.s121.e2" id="qualitative.s121.p0" /></sentence><sentence id="qualitative.s122" text="Verapamil therapy may increase carbamazepine concentrations during combined therapy"><entity charOffset="0-8" id="qualitative.s122.e0" text="Verapamil" type="active-ingredient" /><entity charOffset="31-43" id="qualitative.s122.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s122.e0" e2="qualitative.s122.e1" id="qualitative.s122.p0" /></sentence><sentence id="qualitative.s123" text="7.20 Rifampin Therapy with rifampin may markedly reduce oral verapamil bioavailability. 7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. "><entity charOffset="61-69" id="qualitative.s123.e0" text="verapamil" type="active-ingredient" /><entity charOffset="106-114" id="qualitative.s123.e1" text="verapamil" type="active-ingredient" /><entity charOffset="5-12" id="qualitative.s123.e2" text="rifampin" type="active-ingredient" /><entity charOffset="27-34" id="qualitative.s123.e3" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s123.e1" e2="qualitative.s123.e3" id="qualitative.s123.p0" /></sentence><sentence id="qualitative.s124" text="7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. "><entity charOffset="18-26" id="qualitative.s124.e0" text="Verapamil" type="active-ingredient" /><entity charOffset="5-16" id="qualitative.s124.e1" text="theophylline" type="active-ingredient" /><entity charOffset="88-99" id="qualitative.s124.e2" text="theophylline" type="active-ingredient" /><pair ddi="true" e1="qualitative.s124.e0" e2="qualitative.s124.e2" id="qualitative.s124.p0" /></sentence><sentence id="qualitative.s125" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="18-26" id="qualitative.s125.e0" text="verapamil" type="active-ingredient" /><entity charOffset="128-137" id="qualitative.s125.e1" text="adriamycin" type="drug-product" /><pair ddi="true" e1="qualitative.s125.e0" e2="qualitative.s125.e1" id="qualitative.s125.p0" /></sentence><sentence id="qualitative.s126" text="Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil"><entity charOffset="88-99" id="qualitative.s126.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="151-159" id="qualitative.s126.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s126.e0" e2="qualitative.s126.e1" id="qualitative.s126.p0" /></sentence><sentence id="qualitative.s127" text="The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged"><entity charOffset="64-72" id="qualitative.s127.e0" text="verapamil" type="active-ingredient" /><entity charOffset="198-206" id="qualitative.s127.e1" text="verapamil" type="active-ingredient" /><entity charOffset="24-33" id="qualitative.s127.e2" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s127.e1" e2="qualitative.s127.e2" id="qualitative.s127.p0" /></sentence><sentence id="qualitative.s128" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. "><entity charOffset="117-125" id="qualitative.s128.e0" text="vindesine" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s128.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s128.e0" e2="qualitative.s128.e1" id="qualitative.s128.p0" /></sentence><sentence id="qualitative.s129" text="Verapamil therapy may increase serum levels of cyclosporine"><entity charOffset="47-58" id="qualitative.s129.e0" text="cyclosporine" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s129.e1" text="Verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s129.e0" e2="qualitative.s129.e1" id="qualitative.s129.p0" /></sentence><sentence id="qualitative.s130" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="140-148" id="qualitative.s130.e0" text="cisplatin" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s130.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s130.e0" e2="qualitative.s130.e1" id="qualitative.s130.p0" /></sentence><sentence id="qualitative.s131" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. "><entity charOffset="18-26" id="qualitative.s131.e0" text="verapamil" type="active-ingredient" /><entity charOffset="213-221" id="qualitative.s131.e1" text="verapamil" type="active-ingredient" /><entity charOffset="77-88" id="qualitative.s131.e2" text="procarbazine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s131.e1" e2="qualitative.s131.e2" id="qualitative.s131.p0" /></sentence><sentence id="qualitative.s132" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. "><entity charOffset="18-26" id="qualitative.s132.e0" text="verapamil" type="active-ingredient" /><entity charOffset="213-221" id="qualitative.s132.e1" text="verapamil" type="active-ingredient" /><entity charOffset="68-74" id="qualitative.s132.e2" text="oncovin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s132.e1" e2="qualitative.s132.e2" id="qualitative.s132.p0" /></sentence><sentence id="qualitative.s133" text="A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil"><entity charOffset="121-129" id="qualitative.s133.e0" text="verapamil" type="active-ingredient" /><entity charOffset="29-39" id="qualitative.s133.e1" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s133.e0" e2="qualitative.s133.e1" id="qualitative.s133.p0" /></sentence><sentence id="qualitative.s134" text="Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. "><entity charOffset="70-78" id="qualitative.s134.e0" text="digitoxin" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s134.e1" text="Verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s134.e0" e2="qualitative.s134.e1" id="qualitative.s134.p0" /></sentence><sentence id="qualitative.s135" text="7.8 Antineoplastic Agents Verapamil can increase doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. "><entity charOffset="49-59" id="qualitative.s135.e0" text="doxorubicin" type="active-ingredient" /><entity charOffset="26-34" id="qualitative.s135.e1" text="Verapamil" type="active-ingredient" /><entity charOffset="87-95" id="qualitative.s135.e2" text="Verapamil" type="active-ingredient" /><entity charOffset="282-290" id="qualitative.s135.e3" text="Verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s135.e0" e2="qualitative.s135.e3" id="qualitative.s135.p0" /></sentence><sentence id="qualitative.s136" text="The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged"><entity charOffset="24-33" id="qualitative.s136.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="64-72" id="qualitative.s136.e1" text="verapamil" type="active-ingredient" /><entity charOffset="198-206" id="qualitative.s136.e2" text="verapamil" type="active-ingredient" /><pair ddi="false" e1="qualitative.s136.e0" e2="qualitative.s136.e2" id="qualitative.s136.p0" /></sentence><sentence id="qualitative.s137" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible"><entity charOffset="99-106" id="qualitative.s137.e0" text="warfarin" type="active-ingredient" /><entity charOffset="61-70" id="qualitative.s137.e1" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="qualitative.s137.e0" e2="qualitative.s137.e1" id="qualitative.s137.p0" /></sentence><sentence id="qualitative.s138" text="Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital"><entity charOffset="60-68" id="qualitative.s138.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s138.e1" text="Clonazepam" type="active-ingredient" /><pair ddi="false" e1="qualitative.s138.e0" e2="qualitative.s138.e1" id="qualitative.s138.p0" /></sentence><sentence id="qualitative.s139" text="Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital"><entity charOffset="0-9" id="qualitative.s139.e0" text="Clonazepam" type="active-ingredient" /><entity charOffset="71-83" id="qualitative.s139.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s139.e0" e2="qualitative.s139.e1" id="qualitative.s139.p0" /></sentence><sentence id="qualitative.s140" text="Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital"><entity charOffset="88-100" id="qualitative.s140.e0" text="phenobarbital" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s140.e1" text="Clonazepam" type="active-ingredient" /><pair ddi="false" e1="qualitative.s140.e0" e2="qualitative.s140.e1" id="qualitative.s140.p0" /></sentence><sentence id="qualitative.s141" text="Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration"><entity charOffset="0-9" id="qualitative.s141.e0" text="Cimetidine" type="active-ingredient" /><entity charOffset="63-72" id="qualitative.s141.e1" text="meperidine" type="active-ingredient" /><entity charOffset="119-128" id="qualitative.s141.e2" text="meperidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s141.e0" e2="qualitative.s141.e2" id="qualitative.s141.p0" /></sentence><sentence id="qualitative.s142" text="Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration"><entity charOffset="0-9" id="qualitative.s142.e0" text="Cimetidine" type="active-ingredient" /><entity charOffset="116-128" id="qualitative.s142.e1" text="normeperidine" type="metabolite" /><pair ddi="true" e1="qualitative.s142.e0" e2="qualitative.s142.e1" id="qualitative.s142.p0" /></sentence><sentence id="qualitative.s143" text="Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration"><entity charOffset="91-99" id="qualitative.s143.e0" text="acyclovir" type="active-ingredient" /><entity charOffset="56-68" id="qualitative.s143.e1" text="normeperidine" type="metabolite" /><pair ddi="true" e1="qualitative.s143.e0" e2="qualitative.s143.e1" id="qualitative.s143.p0" /></sentence><sentence id="qualitative.s144" text="Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration"><entity charOffset="91-99" id="qualitative.s144.e0" text="acyclovir" type="active-ingredient" /><entity charOffset="25-34" id="qualitative.s144.e1" text="meperidine" type="active-ingredient" /><entity charOffset="59-68" id="qualitative.s144.e2" text="meperidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s144.e0" e2="qualitative.s144.e2" id="qualitative.s144.p0" /></sentence><sentence id="qualitative.s145" text="Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations"><entity charOffset="20-29" id="qualitative.s145.e0" text="nelfinavir" type="active-ingredient" /><entity charOffset="74-85" id="qualitative.s145.e1" text="azithromycin" type="active-ingredient" /><entity charOffset="109-120" id="qualitative.s145.e2" text="azithromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s145.e0" e2="qualitative.s145.e2" id="qualitative.s145.p0" /></sentence><sentence id="qualitative.s146" text="Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels"><entity charOffset="32-38" id="qualitative.s146.e0" text="digoxin" type="active-ingredient" /><entity charOffset="205-211" id="qualitative.s146.e1" text="digoxin" type="active-ingredient" /><entity charOffset="51-78" id="qualitative.s146.e2" text="magnesium-aluminum hydroxide" type="active-ingredient" /><pair ddi="true" e1="qualitative.s146.e1" e2="qualitative.s146.e2" id="qualitative.s146.p0" /></sentence><sentence id="qualitative.s147" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="42-49" id="qualitative.s147.e0" text="warfarin" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s147.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s147.e0" e2="qualitative.s147.e1" id="qualitative.s147.p0" /></sentence><sentence id="qualitative.s148" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="205-213" id="qualitative.s148.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="32-39" id="qualitative.s148.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s148.e0" e2="qualitative.s148.e1" id="qualitative.s148.p0" /></sentence><sentence id="qualitative.s149" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="140-149" id="qualitative.s149.e0" text="amlodipine" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s149.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s149.e0" e2="qualitative.s149.e1" id="qualitative.s149.p0" /></sentence><sentence id="qualitative.s150" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="52-61" id="qualitative.s150.e0" text="furosemide" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s150.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s150.e0" e2="qualitative.s150.e1" id="qualitative.s150.p0" /></sentence><sentence id="qualitative.s151" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="105-112" id="qualitative.s151.e0" text="ramipril" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s151.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s151.e0" e2="qualitative.s151.e1" id="qualitative.s151.p0" /></sentence><sentence id="qualitative.s152" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="205-213" id="qualitative.s152.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="20-29" id="qualitative.s152.e1" text="lovastatin" type="active-ingredient" /><pair ddi="false" e1="qualitative.s152.e0" e2="qualitative.s152.e1" id="qualitative.s152.p0" /></sentence><sentence id="qualitative.s153" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="84-102" id="qualitative.s153.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s153.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s153.e0" e2="qualitative.s153.e1" id="qualitative.s153.p0" /></sentence><sentence id="qualitative.s154" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="126-134" id="qualitative.s154.e0" text="metformin" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s154.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s154.e0" e2="qualitative.s154.e1" id="qualitative.s154.p0" /></sentence><sentence id="qualitative.s155" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="64-70" id="qualitative.s155.e0" text="digoxin" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s155.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="qualitative.s155.e0" e2="qualitative.s155.e1" id="qualitative.s155.p0" /></sentence><sentence id="qualitative.s156" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="205-213" id="qualitative.s156.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="73-81" id="qualitative.s156.e1" text="celecoxib" type="active-ingredient" /><pair ddi="false" e1="qualitative.s156.e0" e2="qualitative.s156.e1" id="qualitative.s156.p0" /></sentence><sentence id="qualitative.s157" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure"><entity charOffset="205-213" id="qualitative.s157.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="115-123" id="qualitative.s157.e1" text="valsartan" type="active-ingredient" /><pair ddi="false" e1="qualitative.s157.e0" e2="qualitative.s157.e1" id="qualitative.s157.p0" /></sentence><sentence id="qualitative.s158" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week"><entity charOffset="35-43" id="qualitative.s158.e0" text="felbamate" type="active-ingredient" /><entity charOffset="359-367" id="qualitative.s158.e1" text="felbamate" type="active-ingredient" /><entity charOffset="0-12" id="qualitative.s158.e2" text="phenobarbital" type="active-ingredient" /><entity charOffset="50-62" id="qualitative.s158.e3" text="phenobarbital" type="active-ingredient" /><entity charOffset="86-98" id="qualitative.s158.e4" text="phenobarbital" type="active-ingredient" /><entity charOffset="173-185" id="qualitative.s158.e5" text="phenobarbital" type="active-ingredient" /><entity charOffset="219-231" id="qualitative.s158.e6" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="qualitative.s158.e1" e2="qualitative.s158.e6" id="qualitative.s158.p0" /></sentence><sentence id="qualitative.s159" text="Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism"><entity charOffset="172-180" id="qualitative.s159.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="98-107" id="qualitative.s159.e1" text="sertraline" type="active-ingredient" /><pair ddi="false" e1="qualitative.s159.e0" e2="qualitative.s159.e1" id="qualitative.s159.p0" /></sentence><sentence id="qualitative.s160" text="Valproate: Felbatol® causes an increase in steady-state valproate concentrations"><entity charOffset="0-8" id="qualitative.s160.e0" text="valproate" type="active-ingredient" /><entity charOffset="57-65" id="qualitative.s160.e1" text="valproate" type="active-ingredient" /><entity charOffset="11-18" id="qualitative.s160.e2" text="Felbatol" type="drug-product" /><pair ddi="true" e1="qualitative.s160.e1" e2="qualitative.s160.e2" id="qualitative.s160.p0" /></sentence><sentence id="qualitative.s161" text="Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration"><entity charOffset="15-22" id="qualitative.s161.e0" text="Felbatol" type="drug-product" /><entity charOffset="136-156" id="qualitative.s161.e1" text="carbamazepine epoxide" type="metabolite" /><pair ddi="true" e1="qualitative.s161.e0" e2="qualitative.s161.e1" id="qualitative.s161.p0" /></sentence><sentence id="qualitative.s162" text="Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration"><entity charOffset="0-12" id="qualitative.s162.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="64-76" id="qualitative.s162.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="136-148" id="qualitative.s162.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="15-22" id="qualitative.s162.e3" text="Felbatol" type="drug-product" /><pair ddi="true" e1="qualitative.s162.e2" e2="qualitative.s162.e3" id="qualitative.s162.p0" /></sentence><sentence id="qualitative.s163" text="Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations"><entity charOffset="0-8" id="qualitative.s163.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="57-65" id="qualitative.s163.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="11-18" id="qualitative.s163.e2" text="Felbatol" type="drug-product" /><pair ddi="true" e1="qualitative.s163.e1" e2="qualitative.s163.e2" id="qualitative.s163.p0" /></sentence><sentence id="qualitative.s164" text="Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol"><entity charOffset="158-174" id="qualitative.s164.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s164.e1" text="Felbamate" type="active-ingredient" /><pair ddi="false" e1="qualitative.s164.e0" e2="qualitative.s164.e1" id="qualitative.s164.p0" /></sentence><sentence id="qualitative.s165" text="However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects."><entity charOffset="68-79" id="qualitative.s165.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="29-40" id="qualitative.s165.e1" text="fexofenadine" type="active-ingredient" /><entity charOffset="139-150" id="qualitative.s165.e2" text="fexofenadine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s165.e0" e2="qualitative.s165.e2" id="qualitative.s165.p0" /></sentence><sentence id="qualitative.s166" text="In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion"><entity charOffset="101-112" id="qualitative.s166.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="148-159" id="qualitative.s166.e1" text="erythromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s166.e0" e2="qualitative.s166.e1" id="qualitative.s166.p0" /></sentence><sentence id="qualitative.s167" text="However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects"><entity charOffset="29-40" id="qualitative.s167.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="139-150" id="qualitative.s167.e1" text="fexofenadine" type="active-ingredient" /><entity charOffset="84-95" id="qualitative.s167.e2" text="erythromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s167.e1" e2="qualitative.s167.e2" id="qualitative.s167.p0" /></sentence><sentence id="qualitative.s168" text="These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption"><entity charOffset="83-94" id="qualitative.s168.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="28-39" id="qualitative.s168.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s168.e0" e2="qualitative.s168.e1" id="qualitative.s168.p0" /></sentence><sentence id="qualitative.s169" text="These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption"><entity charOffset="83-94" id="qualitative.s169.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="44-55" id="qualitative.s169.e1" text="erythromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s169.e0" e2="qualitative.s169.e1" id="qualitative.s169.p0" /></sentence><sentence id="qualitative.s170" text="In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium"><entity charOffset="139-145" id="qualitative.s170.e0" text="lithium" type="active-ingredient" /><entity charOffset="180-186" id="qualitative.s170.e1" text="lithium" type="active-ingredient" /><entity charOffset="87-96" id="qualitative.s170.e2" text="sertraline" type="active-ingredient" /><pair ddi="false" e1="qualitative.s170.e1" e2="qualitative.s170.e2" id="qualitative.s170.p0" /></sentence><sentence id="qualitative.s171" text="Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations"><entity charOffset="23-44" id="qualitative.s171.e0" text="aluminum hydroxide gel" type="drug-product" /><entity charOffset="84-94" id="qualitative.s171.e1" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s171.e0" e2="qualitative.s171.e1" id="qualitative.s171.p0" /></sentence><sentence id="qualitative.s172" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites"><entity charOffset="0-10" id="qualitative.s172.e0" text="Propranolol" type="active-ingredient" /><entity charOffset="110-120" id="qualitative.s172.e1" text="metabolites" type="metabolite" /><pair ddi="true" e1="qualitative.s172.e0" e2="qualitative.s172.e1" id="qualitative.s172.p0" /></sentence><sentence id="qualitative.s173" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites"><entity charOffset="0-10" id="qualitative.s173.e0" text="Propranolol" type="active-ingredient" /><entity charOffset="42-49" id="qualitative.s173.e1" text="diazepam" type="active-ingredient" /><entity charOffset="93-100" id="qualitative.s173.e2" text="diazepam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s173.e0" e2="qualitative.s173.e2" id="qualitative.s173.p0" /></sentence><sentence id="qualitative.s174" text="In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA."><entity charOffset="22-30" id="qualitative.s174.e0" text="glyburide" type="active-ingredient" /><entity charOffset="94-100" id="qualitative.s174.e1" text="AVANDIA" type="drug-product" /><pair ddi="true" e1="qualitative.s174.e0" e2="qualitative.s174.e1" id="qualitative.s174.p0" /></sentence><sentence id="qualitative.s175" text="Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%."><entity charOffset="16-22" id="qualitative.s175.e0" text="AVANDIA" type="drug-product" /><entity charOffset="110-118" id="qualitative.s175.e1" text="glyburide" type="active-ingredient" /><pair ddi="true" e1="qualitative.s175.e0" e2="qualitative.s175.e1" id="qualitative.s175.p0" /></sentence><sentence id="qualitative.s176" text="Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone "><entity charOffset="0-7" id="qualitative.s176.e0" text="Rifampin" type="active-ingredient" /><entity charOffset="102-114" id="qualitative.s176.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="162-174" id="qualitative.s176.e2" text="rosiglitazone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s176.e0" e2="qualitative.s176.e2" id="qualitative.s176.p0" /></sentence><sentence id="qualitative.s177" text="An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. "><entity charOffset="67-79" id="qualitative.s177.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="147-159" id="qualitative.s177.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="113-120" id="qualitative.s177.e2" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s177.e1" e2="qualitative.s177.e2" id="qualitative.s177.p0" /></sentence><sentence id="qualitative.s178" text="An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. "><entity charOffset="67-79" id="qualitative.s178.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="147-159" id="qualitative.s178.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="30-40" id="qualitative.s178.e2" text="gemfibrozil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s178.e1" e2="qualitative.s178.e2" id="qualitative.s178.p0" /></sentence><sentence id="qualitative.s179" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively."><entity charOffset="30-37" id="qualitative.s179.e0" text="Synercid" type="active-ingredient" /><entity charOffset="43-52" id="qualitative.s179.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="282-291" id="qualitative.s179.e2" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s179.e0" e2="qualitative.s179.e2" id="qualitative.s179.p0" /></sentence><sentence id="qualitative.s180" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively."><entity charOffset="30-37" id="qualitative.s180.e0" text="Synercid" type="drug-product" /><entity charOffset="80-88" id="qualitative.s180.e1" text="midazolam" type="active-ingredient" /><entity charOffset="297-305" id="qualitative.s180.e2" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s180.e0" e2="qualitative.s180.e2" id="qualitative.s180.p0" /></sentence><sentence id="qualitative.s181" text="The exposure to quinidine was not importantly changed in the presence of nifedipine"><entity charOffset="16-24" id="qualitative.s181.e0" text="quinidine" type="active-ingredient" /><entity charOffset="73-82" id="qualitative.s181.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s181.e0" e2="qualitative.s181.e1" id="qualitative.s181.p0" /></sentence><sentence id="qualitative.s182" text="Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration"><entity charOffset="57-66" id="qualitative.s182.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="108-117" id="qualitative.s182.e1" text="metoprolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s182.e0" e2="qualitative.s182.e1" id="qualitative.s182.p0" /></sentence><sentence id="qualitative.s183" text="Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration"><entity charOffset="108-117" id="qualitative.s183.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="73-83" id="qualitative.s183.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s183.e0" e2="qualitative.s183.e1" id="qualitative.s183.p0" /></sentence><sentence id="qualitative.s184" text="Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration"><entity charOffset="34-42" id="qualitative.s184.e0" text="quinidine" type="active-ingredient" /><entity charOffset="108-117" id="qualitative.s184.e1" text="metoprolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s184.e0" e2="qualitative.s184.e1" id="qualitative.s184.p0" /></sentence><sentence id="qualitative.s185" text="Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)"><entity charOffset="58-71" id="qualitative.s185.e0" text="metoclopramide" type="active-ingredient" /><entity charOffset="189-201" id="qualitative.s185.e1" text="acetaminophen" type="active-ingredient" /><pair ddi="true" e1="qualitative.s185.e0" e2="qualitative.s185.e1" id="qualitative.s185.p0" /></sentence><sentence id="qualitative.s186" text="Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)"><entity charOffset="58-71" id="qualitative.s186.e0" text="metoclopramide" type="active-ingredient" /><entity charOffset="204-215" id="qualitative.s186.e1" text="tetracycline" type="active-ingredient" /><pair ddi="true" e1="qualitative.s186.e0" e2="qualitative.s186.e1" id="qualitative.s186.p0" /></sentence><sentence id="qualitative.s187" text="Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin),"><entity charOffset="58-71" id="qualitative.s187.e0" text="metoclopramide" type="active-ingredient" /><entity charOffset="80-86" id="qualitative.s187.e1" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s187.e0" e2="qualitative.s187.e1" id="qualitative.s187.p0" /></sentence><sentence id="qualitative.s188" text="Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)"><entity charOffset="58-71" id="qualitative.s188.e0" text="metoclopramide" type="active-ingredient" /><entity charOffset="237-248" id="qualitative.s188.e1" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s188.e0" e2="qualitative.s188.e1" id="qualitative.s188.p0" /></sentence><sentence id="qualitative.s189" text="Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)"><entity charOffset="228-234" id="qualitative.s189.e0" text="ethanol" type="active-ingredient" /><entity charOffset="58-71" id="qualitative.s189.e1" text="metoclopramide" type="active-ingredient" /><pair ddi="true" e1="qualitative.s189.e0" e2="qualitative.s189.e1" id="qualitative.s189.p0" /></sentence><sentence id="qualitative.s190" text="Because the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment"><entity charOffset="126-132" id="qualitative.s190.e0" text="insulin" type="active-ingredient" /><entity charOffset="22-35" id="qualitative.s190.e1" text="metoclopramide" type="active-ingredient" /><pair ddi="true" e1="qualitative.s190.e0" e2="qualitative.s190.e1" id="qualitative.s190.p0" /></sentence><sentence id="qualitative.s191" text="Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam"><entity charOffset="27-36" id="qualitative.s191.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="93-102" id="qualitative.s191.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="0-12" id="qualitative.s191.e2" text="Carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s191.e1" e2="qualitative.s191.e2" id="qualitative.s191.p0" /></sentence><sentence id="qualitative.s192" text="Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate "><entity charOffset="61-89" id="qualitative.s192.e0" text="tenofovir disoproxil fumarate" type="active-ingredient" /><entity charOffset="12-21" id="qualitative.s192.e1" text="didanosine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s192.e0" e2="qualitative.s192.e1" id="qualitative.s192.p0" /></sentence></document>